Results 171 to 180 of about 7,693 (199)

Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis

Cancer Discovery, 2022
Abstract The primary endpoint of 35% or greater reduction in spleen volume was met with manageable safety.
openaire   +2 more sources

Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice

Hepatology Research, 2023
AbstractAimAcute‐on‐chronic liver failure (ACLF), a disease with poor prognosis, is reportedly caused by cellular senescence due to mitochondrial dysfunction. In this study, we described and analyzed the underlying mechanism of a novel approach for ACLF using ABT263/navitoclax (Navi) that selectively eliminates senescent cells.MethodsIrradiation ...
Yusuke Watanabe, Hiroyuki Abe, Naruhiro Kimura, Yoshihisa Arao, Natsuki Ishikawa, Maeda Yuichiro, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai   +12 more
openaire   +2 more sources

Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells

Gynecologic Oncology, 2013
To evaluate the efficacy of combination of navitoclax, carboplatin and paclitaxel in ovarian cancer.8 ovarian cancer cell lines were treated with either doublet or triplet combinations of navitoclax, carboplatin and paclitaxel. Interactions were assessed by determining a combination index or measuring caspase activity.
Alan Richardson
exaly   +3 more sources

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

Cancer Chemotherapy and Pharmacology, 2014
Navitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor and promotes apoptosis. Thrombocytopenia is a primary dose-limiting toxicity of navitoclax which exhibited a distinct time profile in circulating platelets from that caused by traditional chemotherapies.
Aksana, Kaefer, Jianning, Yang, Peter, Noertersheuser, Sven, Mensing, Rod, Humerickhouse, Walid, Awni, Hao, Xiong   +6 more
exaly   +3 more sources

Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment

Clinical Pharmacokinetics
Navitoclax, an orally bioavailable B-cell lymphoma-2 (Bcl-2) family protein inhibitor, inhibits antiapoptotic Bcl-2 family proteins (with high affinity to Bcl-XL, Bcl-2, and Bcl-W). Navitoclax in combination with ruxolitinib has been investigated to treat patients with myelofibrosis (MF).Since navitoclax undergoes hepatic metabolism, we evaluated the ...
Maulik Patel, Jalaja Potluri, Thomas Marbury, Eric Lawitz, Juan Carlos Rondon, David M. Hoffman, Satya R. Siddani, Kennan C. Marsh, Elaine J. Kim, Muhammad Erfan Uddin, Rajeev M. Menon, Akshanth R. Polepally   +11 more
openaire   +2 more sources

Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models

Molecular Cancer Therapeutics, 2012
Abstract To examine the potential of combining Bcl-2 family inhibitors with chemotherapy in ovarian cancer, we evaluated a panel of 27 ovarian cancer cell lines for response to the combination of navitoclax (formerly ABT-263) and paclitaxel or gemcitabine. The majority of cell lines exhibited a greater than additive response to either
Maureen, Wong, Nguyen, Tan, Jiping, Zha, Franklin V, Peale, Peng, Yue, Wayne J, Fairbrother, Lisa D, Belmont   +6 more
openaire   +2 more sources

Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling

Biochemical Pharmacology, 2022
Compounds with senolysis activity are discovered in recent years, featuring by their capacity to specifically eliminate senescent cells in vitro or in vivo. These compounds, referring to as Senolytics, provide a new method for aging counteraction and probably for geriatric disease amelioration.
Weitong, Xu, Tingting, Zhao, Honghan, Chen, Ning, Huang, Hui, Gong, Jian, Zhang, Yu, Yang, Tiepeng, Li, Gongchang, Zhang, Chuhui, Gong, Ming, Yang, Hengyi, Xiao   +11 more
openaire   +2 more sources

A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts

Nanomedicine: Nanotechnology, Biology, and Medicine, 2016
Cancer-associated fibroblasts (CAFs) play a vitally important role during tumor progression. Navitoclax (Nav) can specifically induce apoptosis in CAFs. The present study aims to develop a novel CAF-targeted nanoliposome for cancer therapy. Nav-loaded nanoliposomes modified with peptide FH (FH-SSL-Nav), which specifically binds to tenascin C, a protein
Binlong Chen, Wenbing Dai, Qiang Zhang
exaly   +3 more sources

Combined Usage of Navitoclax and A-1210477 to Treat AcuteLymphoblastic Leukemia

MedScien, 2023
Mcl-1 protein has been a key targeted therapeutic protein in treating acute lymphoblastic leukemia because of itsresistance to other previously known drugs. However, a newly synthesized chemical A-1210477 has proven to possessenough affinity to bind to the Mcl-1 protein and disrupt its normal function. As a result, scientists started to test thepotency
openaire   +1 more source

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia

Leukemia, 2018
Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3-ITD is associated with unfavorable prognosis and represents a particularly challenging treatment group. To identify novel effective therapies for this AML subtype, we screened patient cells and engineered cell models with over 300 compounds. We found that mouse hematopoietic progenitors
Kumar Ashwini, Yadav Bhagwan, Heckman Caroline A., Kivioja Jarno L., Porkka Kimmo, Javarappa Komal K., Kontro Mika, Majumder Muntasir M., Eldfors Samuli, Kumar Ashwini, Yadav Bhagwan, Heckman Caroline A., Kivioja Jarno L., Porkka Kimmo, Javarappa Komal K., Kontro Mika, Majumder Muntasir M., Eldfors Samuli   +17 more
openaire   +2 more sources